GlassScriptPhysician profile
Jacob D Kelton
NPI 1730583840
$2,304.17
in general payments reported to CMS, 2019-2025
14 companies · $1,112 in 2025
The $1,112 reported for 2025 was more than what 89% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,193 · 2025: $1,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,272 · Education: $31.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,272.41 |
| Education | $31.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $371.55 | 2024-2025 | Tarpeyo |
| Ardelyx, INC. | $296.65 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $282.12 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.49 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $228.09 | 2024-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $219.52 | 2024-2025 | Velphoro, Velphoro |
| Amgen INC. | $206.12 | 2024-2025 | Tavneos, Parsabiv, Aranesp |
| Novartis Pharmaceuticals Corporation | $181.55 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $80.89 | 2024 | Lupkynis |
| Travere Therapeutics, INC. | $58.26 | 2025 | Filspari |
| Novo Nordisk INC | $50.84 | 2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $34.45 | 2024-2025 | Jesduvroq, Benlysta |
| Opko Pharmaceuticals, LLC | $31.37 | 2024 | Rayaldee |
| Kyowa Kirin, INC. | $20.27 | 2024 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Kelton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.